VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 25, 2021 07:00 ET
|
VBL Therapeutics
Conference Call and Webcast at 8:30 a.m. EDT Today Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125...
VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25
March 17, 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and full year results for the period ended December 31, 2020 on Thursday, March...
VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences
March 08, 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences: H.C...
VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
March 04, 2021 07:00 ET
|
VBL Therapeutics
Analysis shows a CA-125 response of at least 58% in the VB-111 treatment armPublished online in Gynecologic Oncology TEL AVIV, Israel, March 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:...
VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
March 01, 2021 07:00 ET
|
VBL Therapeutics
Investigator-sponsored study will be conducted at seven centers in the U.S. TEL AVIV, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that patient dosing...
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
February 22, 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the...
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
January 27, 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s...
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
January 15, 2021 07:15 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
December 29, 2020 07:00 ET
|
VBL Therapeutics
Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL...
VBL Therapeutics Announces Insider Buying
December 07, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...